Determination of Insulin-Like Growth Factor-I in the Monitoring of Growth Hormone Treatment with Respect to Efficacy of Treatment and Side Effects: Should Potential Risks of Cardiovascular Disease and Cancer Be Considered? | Citedby Results | Hormone Research in Paediatrics | Karger Publishers

Skip to Main Content

Skip Nav Destination

Determination of Insulin-Like Growth Factor-I in the Monitoring of Growth Hormone Treatment with Respect to Efficacy of Treatment and Side Effects: Should Potential Risks of Cardiovascular Disease and Cancer Be Considered?

Hormone Research (1999) 51 (Suppl. 3): 141–148.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

Amount and quality of dietary proteins during the first two years of life in relation to NCD risk in adulthood

K.F. Michaelsen
A. Larnkjær
C. Mølgaard

Nutrition, Metabolism and Cardiovascular Diseases (2012) 22 (10): 781.

Signaling pathway of insulin and insulin-like growth factor 1 (IGF-1) as a potential regulator of lifespan

O. V. Chistyakova

Journal of Evolutionary Biochemistry and Physiology (2008) 44 (1): 1.

Cow's Milk and Linear Growth in Industrialized and Developing Countries

Camilla Hoppe
Christian Mølgaard
Kim F. Michaelsen

Annual Review of Nutrition (2006) 26 (1): 131.

The insulin/IGF-1 signaling in mammals and its relevance to human longevity

Marielisa Rincon
Eric Rudin
Nir Barzilai

Experimental Gerontology (2005) 40 (11): 873.

Insulin-like growth factor I (IGF-I) replacement therapy increases albumin concentration in liver cirrhosis: Results of a pilot randomized controlled clinical trial

Mariam Conchillo
Robert J. de Knegt
Marina Payeras
Jorge Quiroga
Bruno Sangro
Jose-Ignacio Herrero
Inma Castilla-Cortazar
Jan Frystyk
Allan Flyvbjerg
Carl Yoshizawa
Peter L.M. Jansen
Bruce Scharschmidt
Jesús Prieto

Journal of Hepatology (2005) 43 (4): 630.

New Paradigms for Growth Hormone Therapy in Children

Lawrence Wetterau
Pinchas Cohen

Hormone Research in Paediatrics (2000) 53 (Suppl. 3): 31.

Current Awareness

Pharmacoepidemiology and Drug Safety (2000) 9 (4): 341.